Diffuse Axonal Injury

Diffuse axonal injury is a traumatic brain injury caused by rapid acceleration/deceleration and rotational forces that shear white matter axons, resulting in widespread disruption of neuronal connectivity. [1-2] It is found across all TBI severities and is the predominant pathologic mechanism underlying concussion through severe TBI. [3-4] DAI is graded by depth of injury: Grade 1 (lobar white matter), Grade 2 (corpus callosum), and Grade 3 (brainstem), with brainstem involvement carrying the worst prognosis. [5-6]

1. History

• Mechanism: High-speed motor vehicle collisions, motorcycle/bicycle crashes, falls from height, blast injuries, sports-related impacts — any event producing significant acceleration/deceleration or rotational forces [2][7]
• Loss of consciousness: Immediate and often prolonged; patients with severe DAI are typically comatose from the moment of injury, distinguishing DAI from expanding mass lesions where lucid intervals may occur [1][8]
• Post-traumatic amnesia: Duration correlates with severity; PTA >24 hours suggests significant injury
• Key questions: Speed of impact, use of restraints/helmets, ejection from vehicle, height of fall, prior TBIs, anticoagulant/antiplatelet use
• Important negatives: Absence of a lucid interval (suggests diffuse rather than focal pathology), no history of seizure disorder, no prior neurodegenerative disease

2. Alarm Features

• Immediate coma without a lucid interval after high-energy mechanism [1-2]
• GCS ≤8 at presentation — defines severe TBI and mandates airway protection [9]
• Pupillary abnormalities: Fixed, dilated, or asymmetric pupils suggest brainstem involvement (Grade 3 DAI) or herniation [5][10]
• Decerebrate or decorticate posturing, especially with afferent stimulation
• Paroxysmal sympathetic hyperactivity (PSH): Episodic tachycardia, hypertension, diaphoresis, hyperthermia, and posturing — strongly associated with DAI and portends worse outcomes [11-12]
• Midline traumatic subarachnoid hemorrhage or intraventricular hemorrhage on CT — surrogate markers of severe DAI [13-14]

3. Medications

• Seizure prophylaxis: Levetiracetam (preferred in modern practice) or phenytoin for 7 days only to prevent early post-traumatic seizures; do not continue beyond 7 days unless seizure activity occurs after 24 hours. Valproic acid is not recommended due to increased mortality risk [10][15]
• Osmotherapy for elevated ICP: Mannitol 0.25–1.0 g/kg bolus or hypertonic saline bolus [10]
• Sedation/analgesia: Propofol, midazolam, fentanyl — titrated to ICP targets
• PSH management: Beta-blockers (propranolol), gabapentin, bromocriptine, opioids, benzodiazepines, dantrolene [10][16]
• Contraindicated: Corticosteroids — associated with increased mortality in TBI (CRASH trial). Avoid prolonged hyperventilation (PaCO₂ <30 mmHg) without advanced monitoring [2][17]
• Anticoagulation reversal: Emergent reversal if on warfarin or DOACs with intracranial hemorrhage [10]

4. Diet

• NPO initially in comatose patients pending airway management
• Early enteral nutrition (within 24–72 hours) via nasogastric or post-pyloric tube is recommended in severe TBI to reduce catabolism and improve outcomes
• Caloric targets: 25–30 kcal/kg/day; protein 1.5–2 g/kg/day to counteract hypermetabolic state
• Avoid hyperglycemia: Maintain glucose control but avoid hypoglycemia, which is particularly harmful to the injured brain [2]
• Long-term: Nutritional optimization during rehabilitation; dysphagia assessment before oral feeding

5. Review of Systems

• Neurologic: Level of consciousness, pupillary reactivity, motor responses, seizure activity, signs of PSH
• Respiratory: Aspiration risk, neurogenic pulmonary edema, ventilator requirements
• Cardiovascular: Tachycardia, hypertension (sympathetic storming vs. hypovolemia), ECG changes [18]
• GI: Stress ulcer risk, ileus
• Hematologic: Coagulopathy (trauma-induced or medication-related), DVT risk
• Endocrine: Pituitary dysfunction (diabetes insipidus, SIADH, adrenal insufficiency) — common after DAI due to hypothalamic-pituitary axis vulnerability

6. Collateral History and Family History

• Collateral: Witnesses to mechanism, pre-hospital GCS, any lucid interval, medications (especially anticoagulants/antiplatelets), substance use, baseline functional status
• Family history: Prior neurodegenerative disease, seizure disorders
• Social context: Occupation (military, contact sports), prior TBIs/concussions (cumulative risk for chronic traumatic encephalopathy), advance directives, surrogate decision-maker identification [3]

7. Risk Factors

• High-speed motor vehicle accidents (most common mechanism, ~70% of DAI cases) [14]
• Young males (median age ~31–41 years, ~79% male) [14][19]
• Motorcycle/bicycle crashes, falls from height, blast injuries [7]
• Contact sports with repeated subconcussive impacts [3]
• Absence of protective equipment (seatbelts, helmets)
• Anticoagulant/antiplatelet use — increases hemorrhagic component
• Prior TBI — may increase vulnerability to axonal injury

8. Differential Diagnosis

• Epidural/subdural hematoma: Lucid interval may be present; focal mass effect on CT; surgical emergency [9]
• Cerebral contusions: Focal hemorrhagic lesions at gray-white junction, often frontal/temporal; frequently coexist with DAI [2]
• Diffuse cerebral edema/hypoxic-ischemic injury: Consider if prolonged hypotension or hypoxia occurred; loss of gray-white differentiation on CT [20]
• Cerebral venous sinus thrombosis: Can mimic diffuse injury; consider if atypical hemorrhage pattern
• Status epilepticus: Non-convulsive status can cause prolonged coma; EEG is essential
• Toxic/metabolic encephalopathy: Alcohol, drugs, hypoglycemia — must be excluded
• Fat embolism syndrome: Petechial hemorrhages in white matter after long bone fractures; can mimic DAI on MRI

9. Past Medical History

• Prior TBI or concussions (cumulative axonal vulnerability) [3-4]
• Pre-existing seizure disorder
• Neurodegenerative conditions
• Coagulopathy or anticoagulant use
• Psychiatric history (impacts rehabilitation trajectory) [21]
• Substance use disorders

10. Physical Exam

• Vital signs: Hypertension and tachycardia (sympathetic surge); hypotension suggests hemorrhagic shock from polytrauma
• GCS assessment: Document each component (Eye, Verbal, Motor) separately [10]
• Pupils: Size, reactivity, symmetry — fixed/dilated pupils suggest brainstem DAI or herniation; quantitative pupillometry is more reliable than clinical assessment [10]
• Motor exam: Decerebrate posturing (Grade 3), decorticate posturing, withdrawal, or no response
• Signs of basilar skull fracture: Raccoon eyes, Battle sign, hemotympanum, CSF rhinorrhea/otorrhea
• Fundoscopy: Retinal hemorrhages (consider non-accidental trauma in pediatrics)
• Full trauma survey: Polytrauma is common; cervical spine precautions mandatory

11. Lab Studies

• Standard trauma labs: CBC, BMP, coagulation studies (PT/INR, PTT, fibrinogen), type and screen, blood alcohol, urine drug screen
• Serum biomarkers (emerging clinical utility):
  • Neurofilament light (NfL): Peaks at 10 days to 6 weeks; strongest predictor of functional outcomes at 1 year; correlates with DTI measures of axonal injury; remains elevated for years [22-23]
  • GFAP: Peaks acutely; best for detecting intracranial pathology on CT (AUC 0.77–0.93); shows biphasic release with secondary elevation years post-injury [22][24-25]
  • UCH-L1: Acute marker; FDA-cleared with GFAP for ruling out CT-positive findings in mild TBI [26]
  • S100B: Prognostic value for functional outcome [27]
• Monitoring: Serial sodium (risk of DI/SIADH), glucose, hemoglobin (maintain >7 g/dL), osmolality if on osmotherapy [10]

12. Imaging

• CT head (first-line): Rapid, widely available; low sensitivity for DAI as it is a cellular-level injury. May show: [14][28]
  • Punctate hemorrhages at gray-white junction, corpus callosum, or brainstem [29]
  • Intraventricular hemorrhage and midline traumatic SAH — surrogate markers of severe DAI [13-14]
  • Often normal or near-normal despite severe clinical presentation — this discrepancy is a hallmark of DAI [8]
• MRI (gold standard for DAI detection): [10][30]
  • SWI/GRE (T2</em>): Most sensitive for hemorrhagic microbleeds (hemosiderin deposits)
  • FLAIR: Detects non-hemorrhagic white matter lesions
  • DWI/ADC: Identifies acute cytotoxic edema in injured axons; restricted diffusion in white matter tracts [31]
  • DTI (diffusion tensor imaging): Most sensitive for quantifying axonal injury via fractional anisotropy; can detect injury even with normal conventional MRI [32-33]
  • Recommended protocol: T1, T2, FLAIR, DWI/ADC, SWI (or T2<em>-GRE)</em> [10]
• When imaging is unnecessary: CT is always indicated in acute moderate-severe TBI; MRI is indicated when clinical severity is disproportionate to CT findings, or for prognostication [30]

13. Special Tests

• DAI Grading (Adams Classification)[5][19]
• PSH Assessment Measure (PSH-AM): Clinical feature scale + diagnosis likelihood tool for diagnosing paroxysmal sympathetic hyperactivity [16]
• Quantitative pupillometry: More reliable than clinical assessment for pupillary reactivity [10]
• Continuous EEG monitoring: To detect non-convulsive seizures [10]
• Cerebral microdialysis: Research/specialized centers; measures lactate/pyruvate ratio, glucose, glutamate in brain extracellular fluid [1]

14. ECG

• Indications: All patients with severe TBI should have continuous cardiac monitoring
• Expected findings in acute TBI: [18]
  • Sinus tachycardia (most common)
  • ST-segment changes (depression or elevation), T-wave inversions, "cerebral T waves" (deep, symmetric)
  • QT prolongation — risk of torsades de pointes
  • Premature ventricular complexes
• PSH episodes: Paroxysmal tachycardia, hypertension [16]
• Key point: ECG changes peak at ~24 hours and are usually transient; must exclude primary cardiac pathology, especially in older patients [18]

15. Assessment

• DAI is a clinical-radiographic diagnosis: suspect when coma occurs immediately after high-energy trauma with CT findings disproportionately mild relative to clinical severity [8]
• Severity stratification is based on depth of injury (Grades 1–3), with brainstem involvement being the strongest predictor of poor outcome [5-6]
• Typical presentation: Immediate coma without lucid interval, no significant mass lesion on CT, often normal or near-normal CT
• Atypical presentations: Mild TBI with subtle cognitive deficits and normal imaging; DAI is the predominant pathology even in concussion [3][33]
• Complications: PSH (~10–15% of severe TBI), post-traumatic epilepsy, hydrocephalus, pituitary dysfunction, chronic traumatic encephalopathy with repeated injuries, progressive neurodegeneration [4][16][34]
• Prognosis: 51% of DAI patients achieve favorable long-term functional outcome (GOSE 6–8); even Grade 3 patients can recover favorably; independent prognostic factors include age, pupillary reaction, hemoglobin, DAI grade, and return of consciousness ≤7 days [35]

16. Treatment Plan

Initial stabilization (ATLS principles): [10][36]

• Airway: Endotracheal intubation for GCS ≤8
• Breathing: Maintain SpO₂ ≥94%; avoid hypoxia
• Circulation: Maintain SBP ≥100 mmHg (age ≥50) or ≥110 mmHg (age 15–49); avoid hypotension
• Head of bed elevated 30–45°, head midline

ICU management: [10]

• ICP monitoring if GCS ≤8 with abnormal CT (or normal CT with ≥2 risk factors)
• Maintain CPP ≥60 mmHg (target 60–70 mmHg)
• Osmotherapy: Mannitol 0.25–1.0 g/kg bolus or hypertonic saline for ICP >22 mmHg
• Seizure prophylaxis: Levetiracetam or phenytoin × 7 days [10][15]
• Temperature management: Treat fever >38°C aggressively [10]
• Avoid hyponatremia; maintain Hgb >7 g/dL
• PaCO₂ target 35–38 mmHg (avoid aggressive hyperventilation) [10]

No proven neuroprotective pharmacotherapy exists for DAI. [1][17] Progesterone, ciclosporin-A, and erythropoietin have been studied without definitive clinical benefit. [17]

Rehabilitation: [10][37]

• Early multidisciplinary rehabilitation (PT, OT, SLP, neuropsychology) beginning on day of admission
• Specialized inpatient rehabilitation when medically stable
• Cognitive rehabilitation for memory/attention deficits
• Graded physical exercise programs

17. Disposition

• ICU admission: All patients with GCS ≤8, abnormal CT, or clinical concern for DAI [10]
• Observation: Patients with GCS 9–12 and suspected DAI; serial neurologic exams and repeat CT as indicated
• Neurosurgical consultation: All moderate-severe TBI; DAI itself rarely requires surgery (ICP is usually not markedly elevated), but coexisting mass lesions may [2][9]
• Transfer to Level 1 trauma center: If presenting to a facility without neurosurgical capabilities [38]
• Discharge to inpatient rehabilitation: When medically stable; patients with moderate-severe TBI who receive specialized postacute rehabilitation have higher probability of functional independence [10]

18. Follow Up / Return Precautions

• Inpatient: Serial GCS and pupillary assessments; repeat CT for any neurologic decline; EEG monitoring for subclinical seizures [10]
• Post-discharge follow-up: [10][21]
  • Neurosurgery/neurology follow-up within 2–4 weeks
  • Neuropsychological testing at 3–6 months to assess cognitive recovery
  • Referral to TBI specialty clinic if persistent symptoms beyond 30 days [21]
  • Screen for depression, anxiety, PTSD — common after TBI [21]
• Return precautions for patients/families:
  • New or worsening headache, vomiting, seizures, confusion, weakness, vision changes → immediate ED return
  • Behavioral changes, sleep disturbances, or cognitive decline warrant reassessment
• Expected recovery: Grade 1 DAI patients show fastest recovery (mean ~9 days to follow commands); discharge GCS is often comparable across grades. Over 50% of DAI patients achieve favorable long-term outcome, though recovery may continue for months to years [19][35]
• Long-term monitoring: Serum NfL may remain elevated for years, reflecting ongoing neurodegeneration; progressive brain atrophy has been documented >5 years post-injury. DAI is a risk factor for chronic traumatic encephalopathy and Alzheimer-like pathology [4][23][34]

Images

References

1. Current Opportunities for Clinical Monitoring of Axonal Pathology in Traumatic Brain Injury. — Tsitsopoulos PP, Abu Hamdeh S, Marklund N. Frontiers in Neurology. 2017.

2. Moderate and Severe Traumatic Brain Injury in Adults. — Maas AI, Stocchetti N, Bullock R. The Lancet. Neurology. 2008.

3. Traumatic Brain Injuries. — Blennow K, Brody DL, Kochanek PM, et al. Nature Reviews. Disease Primers. 2016.

4. Axonal Pathology in Traumatic Brain Injury. — Johnson VE, Stewart W, Smith DH. Experimental Neurology. 2013.

5. Prevalence and Impact of Diffuse Axonal Injury in Patients With Moderate and Severe Head Injury: A Cohort Study of Early Magnetic Resonance Imaging Findings and 1-Year Outcome. — Skandsen T, Kvistad KA, Solheim O, et al. Journal of Neurosurgery. 2010.

6. MRI and Clinical Variables for Prediction of Outcomes After Pediatric Severe Traumatic Brain Injury. — Ferrazzano PA, Rebsamen S, Field AS, et al. JAMA Network Open. 2024.

7. Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (mTBI) (2021). — Maj Thomas J. Bayuk DO, Amy O. Bowles MD, Lt Col Andrew W. Bursaw DO, et al Department of Veterans Affairs. 2021.

8. Current Concepts: Diffuse Axonal Injury-Associated Traumatic Brain Injury. — Meythaler JM, Peduzzi JD, Eleftheriou E, Novack TA. Archives of Physical Medicine and Rehabilitation. 2001.

9. Severe Traumatic Brain Injury: Targeted Management in the Intensive Care Unit. — Stocchetti N, Carbonara M, Citerio G, et al. The Lancet. Neurology. 2017.

10. Best Practices In The Management Of Traumatic Brain Injury. — Geoffrey T. Manley MD PhD, Gregory W. Albert MD MPH FAANS FACS FAAP, Gretchen M. Brophy PharmD BCPS FCCP FCCM FNCS MCCM, et al American College of Surgeons (2024). 2024.

11. Heart Rate Variability and Cerebral Autoregulation in Patients With Traumatic Brain Injury With Paroxysmal Sympathetic Hyperactivity Syndrome. — Burzyńska M, Woźniak J, Urbański P, et al. Neurocritical Care. 2025.

12. Admission Features Associated With Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury: A Case-Control Study. — Podell JE, Miller SS, Jaffa MN, et al. Critical Care Medicine. 2021.

13. Traumatic Midline Subarachnoid Hemorrhage on Initial Computed Tomography as a Marker of Severe Diffuse Axonal Injury. — Mata-Mbemba D, Mugikura S, Nakagawa A, et al. Journal of Neurosurgery. 2018.

14. Early Computed Tomography for Acute Post-Traumatic Diffuse Axonal Injury: A Systematic Review. — Figueira Rodrigues Vieira G, Guedes Correa JF. Neuroradiology. 2020.

15. Brain Trauma Foundation Guidelines for the Management of Penetrating Traumatic Brain Injury, Second Edition. — Randy Bell, Shelley Selph, Jamshid Ghajar, et al Brain Trauma Foundation (2025). 2025.

16. Paroxysmal Sympathetic Hyperactivity: The Storm After Acute Brain Injury. — Meyfroidt G, Baguley IJ, Menon DK. The Lancet. Neurology. 2017.

17. Early Management of Severe Traumatic Brain Injury. — Rosenfeld JV, Maas AI, Bragge P, et al. Lancet. 2012.

18. The Heart-Brain-Metabolism Axis in Cardiovascular and Neurologic Disease. — Tardo DT, Cortes-Canteli M, Fuster V, Sachdev PS, Kovacic JC. Journal of the American College of Cardiology. 2025.

19. Diffuse Axonal Injury Pattern Predicts Timing of in-Hospital Neurologic Recovery: A Retrospective Case Series. — El-Abtah ME, Kashkoush A, Petitt JC, et al. World Neurosurgery. 2023.

20. Coma Prognostication After Acute Brain Injury: A Review. — Fischer D, Edlow BL. JAMA Neurology. 2024.

21. Action Collaborative on Traumatic Brain Injury Care: Adapted Clinical Practice Guideline. — Silverberg ND, Lee K, Mikolić A, et al. Annals of Family Medicine. 2025.

22. Time Course and Diagnostic Utility of NfL, Tau, GFAP, and UCH-L1 in Subacute and Chronic TBI. — Shahim P, Politis A, van der Merwe A, et al. Neurology. 2020.

23. Axonal Marker Neurofilament Light Predicts Long-Term Outcomes and Progressive Neurodegeneration After Traumatic Brain Injury. — Graham NSN, Zimmerman KA, Moro F, et al. Science Translational Medicine. 2021.

24. One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury. — Clarke GJB, Skandsen T, Zetterberg H, et al. Frontiers in Neurology. 2021.

25. Glial Fibrillary Acidic Protein Elevations Relate to Neuroimaging Abnormalities After Mild TBI. — Gill J, Latour L, Diaz-Arrastia R, et al. Neurology. 2018.

26. Serum Assessment of Traumatic Axonal Injury: The Correlation of GFAP, T-Tau, UCH-L1, and NfL Levels With Diffusion Tensor Imaging Metrics and Its Prognosis Utility. — Castaño-Leon AM, Sánchez Carabias C, Hilario A, et al. Journal of Neurosurgery. 2023.

27. Incremental Prognostic Value of Acute Serum Biomarkers for Functional Outcome After Traumatic Brain Injury (CENTER-TBI): An Observational Cohort Study. — Helmrich IRAR, Czeiter E, Amrein K, et al. The Lancet. Neurology. 2022.

28. Diffuse Axonal Injury Has a Characteristic Multidimensional MRI Signature in the Human Brain. — Benjamini D, Iacono D, Komlosh ME, et al. Brain : A Journal of Neurology. 2021.

29. Imaging Findings in Diffuse Axonal Injury After Closed Head Trauma. — Parizel PM, Ozsarlak, Van Goethem JW, et al. European Radiology. 1998.

30. ACR Appropriateness Criteria® Head Trauma: 2021 Update. — Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. Journal of the American College of Radiology : JACR. 2021.

31. Structural and Functional Neuroimaging in Mild-to-Moderate Head Injury. — Metting Z, Rödiger LA, De Keyser J, van der Naalt J. The Lancet. Neurology. 2007.

32. Detecting Axonal Injury in Individual Patients After Traumatic Brain Injury. — Jolly AE, Bălăeţ M, Azor A, et al. Brain : A Journal of Neurology. 2021.

33. Diagnosis, Prognosis, and Clinical Management of Mild Traumatic Brain Injury. — Levin HS, Diaz-Arrastia RR. The Lancet. Neurology. 2015.

34. Post-Acute Blood Biomarkers and Disease Progression in Traumatic Brain Injury. — Newcombe VFJ, Ashton NJ, Posti JP, et al. Brain : A Journal of Neurology. 2022.

35. Patients With Diffuse Axonal Injury Can Recover to a Favorable Long-Term Functional and Quality of Life Outcome. — van Eijck M, van der Naalt J, de Jongh M, et al. Journal of Neurotrauma. 2018.

36. The Management of Severe Traumatic Brain Injury in the Initial Postinjury Hours - Current Evidence and Controversies. — Hossain I, Rostami E, Marklund N. Current Opinion in Critical Care. 2023.

37. Multi-Disciplinary Rehabilitation for Acquired Brain Injury in Adults of Working Age. — Turner-Stokes L, Pick A, Nair A, Disler PB, Wade DT. The Cochrane Database of Systematic Reviews. 2015.

38. Early Management of Isolated Severe Traumatic Brain Injury Patients in a Hospital Without Neurosurgical Capabilities: A Consensus and Clinical Recommendations of the World Society of Emergency Surgery (WSES). — Picetti E, Catena F, Abu-Zidan F, et al. World Journal of Emergency Surgery : WJES. 2023.